Results 41 to 50 of about 47,659 (253)

Current use of phosphodiesterase inhibitors in urology

Urology Research and Practice, 2019
The causes of male erectile dysfunction (ED) are quite variable and are now commonly divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow.
Tariq Said Hakky, Lakshay Jain
doaj   +1 more source

Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. [PDF]

PLoS ONE, 2011
BACKGROUND: Phosphodiesterase 7 plays a major role in down-regulation of protein kinase A activity by hydrolyzing cAMP in many cell types. This cyclic nucleotide plays a key role in signal transduction in a wide variety of cellular responses.
Jose A Morales-Garcia, Miriam Redondo, Sandra Alonso-Gil, Carmen Gil, Concepción Perez, Ana Martinez, Angel Santos, Ana Perez-Castillo   +7 more
doaj   +1 more source

Effect of selective phosphodiesterase inhibitors on the rat eosinophil chemotactic response in vitro

Memorias do Instituto Oswaldo Cruz, 1997
In the present study, we have performed a comparative analysis of the effect of selective inhibitors of phosphodiesterase (PDE) type III, IV and V on eosinophil chemotaxis triggered by platelet activating factor (PAF) and leukotriene B4 (LTB4) in vitro ...
Alves Alessandra C, Pires Ana Lucia A, Lagente Vincent, Cordeiro Renato SB, Martins Marco A, Silva Patricia MR e   +5 more
doaj   +3 more sources

Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática Tadalafil as treatment for idiopathic pulmonary arterial hypertension

Arquivos Brasileiros de Cardiologia, 2006
O uso de inibidores de fosfodiesterase, mais especificamente o sildenafil, no tratamento da hipertensão arterial pulmonar mostrou bons resultados, indicados por melhora dos parâmetros hemodinâmicos e da capacidade funcional.
Adriana Castro de Carvalho, André Luiz Hovnanian, Caio Julio César dos Santos Fernandes, Mônica Lapa, Carlos Jardim, Rogério Souza   +5 more
doaj   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility

Therapeutics and Clinical Risk Management, 2014
Eric G Katz,1 Ronny BW Tan,2 Daniel Rittenberg,1 Wayne J Hellstrom3 1Tulane University School of Medicine, New Orleans, LA, USA; 2Department of Urology, Tan Tock Seng Hospital, Singapore; 3Section of Andrology, Department of Urology, Tulane University ...
Katz EG, Tan RBW, Rittenberg D, Hellstrom WJ   +3 more
doaj  

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations

International Journal of General Medicine, 2014
Bader Alsaikhan, Khalid Alrabeeah, Serge CarrierMcGill University Health Centre, Montreal, Quebec, QC, CanadaAbstract: Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age.
Alsaikhan B, Alrabeeah K, Carrier S
doaj  

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source